X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-10-02 | ELTP | Elite Pharmaceuticals Inc /Nv/ | Plassche Douglas | EVP Operations | S - Sale | $0.62 | -800,000 | 3,500,000 | -19% | -$499,200 | ||||||
| DM | 2025-10-01 | ALZN | Alzamend Neuro, Inc. | Ault Milton C III | Dir | S - Sale+OE | $2.41 | -123,366 | 21,232 | -85% | -$296,789 | |||||
| M | 2025-10-01 | JAZZ | Jazz Pharmaceuticals Plc | Cozadd Bruce C | Dir | S - Sale | $137.01 | -5,500 | 408,826 | -1% | -$753,560 | |||||
2025-10-02 | CVKD | Cadrenal Therapeutics, Inc. | Pham Quang X | CEO, COB, 10% | S - Sale | $14.13 | -500 | 402,133 | 0% | -$7,065 | ||||||
2025-10-01 | ARWR | Arrowhead Pharmaceuticals, Inc. | Hamilton James C | Chief Medical Officer | S - Sale | $35.00 | -20,000 | 212,122 | -9% | -$700,000 | ||||||
| M | 2025-10-01 | CARM | Carisma Therapeutics Inc. | Klichinsky Michael | Chief Scientific Officer | S - Sale | $0.26 | -484,347 | 0 | -100% | -$124,343 | |||||
2025-10-01 | CORT | Corcept Therapeutics Inc | Belanoff Joseph K | CEO | S - Sale | $85.08 | -40,000 | 2,781,370 | -1% | -$3,403,253 | ||||||
| D | 2025-10-01 | CORT | Corcept Therapeutics Inc | Lyon Joseph Douglas | See Remarks | S - Sale+OE | $84.75 | -5,000 | 10,277 | -33% | -$423,766 | |||||
| D | 2025-10-01 | CORT | Corcept Therapeutics Inc | Maduck Sean | See Remarks | S - Sale+OE | $85.06 | -20,000 | 117,621 | -15% | -$1,701,232 | |||||
2025-10-02 | ALNY | Alnylam Pharmaceuticals, Inc. | Poulton Jeffrey V. | EVP, CFO | S - Sale | $452.05 | -3,821 | 54,109 | -7% | -$1,727,284 | ||||||
2025-10-02 | ALNY | Alnylam Pharmaceuticals, Inc. | Greenstreet Yvonne | CEO | S - Sale | $452.05 | -8,924 | 65,816 | -12% | -$4,034,085 | ||||||
2025-10-02 | ALNY | Alnylam Pharmaceuticals, Inc. | Tanguler Tolga | EVP, Chief Commercial Officer | S - Sale | $452.05 | -1,405 | 27,438 | -5% | -$635,126 | ||||||
2025-10-02 | ALNY | Alnylam Pharmaceuticals, Inc. | Fitzgerald Kevin Joseph | CSO, EVP, Head of Research | S - Sale | $452.05 | -2,441 | 25,768 | -9% | -$1,103,451 | ||||||
| M | 2025-10-02 | ALNY | Alnylam Pharmaceuticals, Inc. | Garg Pushkal | EVP Chief R, D | S - Sale | $451.76 | -5,959 | 20,902 | -22% | -$2,692,062 | |||||
| M | 2025-10-01 | ARQT | Arcutis Biotherapeutics, Inc. | Watanabe Todd | See Remarks | S - Sale | $19.66 | -45,000 | 1,079,574 | -4% | -$884,649 | |||||
| D | 2025-10-01 | ARQT | Arcutis Biotherapeutics, Inc. | Welgus Howard G. | Dir | S - Sale+OE | $18.92 | -10,000 | 99,744 | -9% | -$189,227 | |||||
2025-10-01 | KPTI | Karyopharm Therapeutics Inc. | Abate Kristin | Chief Accounting Officer | S - Sale | $6.30 | -362 | 10,046 | -3% | -$2,279 | ||||||
2025-10-01 | LGND | Ligand Pharmaceuticals Inc | Kozarich John W | Dir | S - Sale | $179.44 | -467 | 45,055 | -1% | -$83,800 | ||||||
| D | 2025-10-01 | CRNX | Crinetics Pharmaceuticals, Inc. | Pizzuti Dana | Chief Med, Dev Officer | S - Sale+OE | $41.81 | -5,000 | 66,270 | -7% | -$209,050 | |||||
| D | 2025-10-01 | AKRO | Akero Therapeutics, Inc. | Young Jonathan | COO | S - Sale+OE | $47.76 | -12,500 | 256,898 | -5% | -$596,978 | |||||
| D | 2025-10-01 | NUVL | Nuvalent, Inc. | Balcom Alexandra | CFO | S - Sale+OE | $85.48 | -20,000 | 61,734 | -24% | -$1,709,512 | |||||
2025-10-01 | STOK | Stoke Therapeutics, Inc. | Ticho Barry | Chief Medical Officer | S - Sale | $23.64 | -5,343 | 13,126 | -29% | -$126,316 | ||||||
| D | 2025-10-02 | ZLAB | Zai Lab Ltd | Chen Yajing | CFO | S - Sale+OE | $34.25 | -456 | 17,184 | -3% | -$15,617 | |||||
| D | 2025-10-02 | SUPN | Supernus Pharmaceuticals, Inc. | Khattar Jack A. | Pres, CEO | S - Sale+OE | $48.06 | -1,904 | 2,166,833 | 0% | -$91,506 | |||||
2025-10-02 | VRTX | Vertex Pharmaceuticals Inc / Ma | Biller Jonathan | EVP, GC | S - Sale | $404.21 | -694 | 15,653 | -4% | -$280,522 | ||||||
2025-10-02 | LLY | Eli Lilly & Co | Lilly Endowment Inc | 10% | S - Sale | $821.55 | -112,596 | 95,029,382 | 0% | -$92,503,361 | ||||||
2025-10-02 | SNGX | Soligenix, Inc. | Schaber Christopher J | COB, CEO, Pres | P - Purchase | $1.32 | +15,132 | 15,511 | >999% | +$20,000 | ||||||
| M | 2025-09-30 | BYSI | Beyondspring Inc. | Decheng Capital China Life Sciences Usd Fund Iii, L.P. | 10% | S - Sale | $1.80 | -7,665 | 4,347,239 | 0% | -$13,800 | |||||
2025-10-01 | IONS | Ionis Pharmaceuticals Inc | Wender Joseph H | Dir | S - Sale | $65.50 | -16,800 | 92,035 | -15% | -$1,100,385 | ||||||
| DM | 2025-10-01 | IONS | Ionis Pharmaceuticals Inc | Swayze Eric | EVP Research | S - Sale+OE | $66.16 | -27,114 | 37,486 | -42% | -$1,793,744 | |||||
| D | 2025-10-02 | IONS | Ionis Pharmaceuticals Inc | O'Neil Patrick R. | EVP CLO, GC | S - Sale+OE | $67.69 | -64,664 | 57,130 | -53% | -$4,377,054 | |||||
| D | 2025-10-02 | IONS | Ionis Pharmaceuticals Inc | Baroldi Joseph | EVP, Chief Business Officer | S - Sale+OE | $68.01 | -15,000 | 34,997 | -30% | -$1,020,210 | |||||
2025-10-01 | TERN | Terns Pharmaceuticals, Inc. | Kuriakose Emil | Chief Medical Officer | S - Sale | $7.85 | -944 | 51,520 | -2% | -$7,407 | ||||||
| M | 2025-09-30 | ORIC | Oric Pharmaceuticals, Inc. | Chacko Jacob | Pres, CEO | S - Sale | $12.04 | -87,539 | 568,880 | -13% | -$1,053,555 | |||||
2025-10-01 | AMPH | Amphastar Pharmaceuticals, Inc. | Petersen Floyd F. | Dir | S - Sale | $27.20 | -500 | 76,031 | -1% | -$13,602 | ||||||
2025-10-01 | LLY | Eli Lilly & Co | Lilly Endowment Inc | 10% | S - Sale | $821.47 | -215,822 | 95,141,978 | 0% | -$177,290,448 | ||||||
2025-10-01 | LLY | Eli Lilly & Co | Lilly Endowment Inc | 10% | S - Sale | $794.15 | -135,193 | 95,357,800 | 0% | -$107,363,016 | ||||||
| D | 2025-10-01 | MAIA | Maia Biotechnology, Inc. | Smith Stan | Dir | P - Purchase | $1.30 | +19,230 | 1,324,289 | +1% | +$24,999 | |||||
| M | 2025-09-30 | KALA | Kala Bio, Inc. | Baker Bros. Advisors LP | Former 10% Owner | S - Sale | $1.45 | -730,408 | 425,006 | -63% | -$1,056,722 | |||||
2025-09-30 | SAVA | Cassava Sciences Inc | Cook Robert Christopher | COO, Legal Office | P - Purchase | $2.91 | +13,725 | 13,725 | New | +$39,940 | ||||||
| DM | 2025-10-01 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $430.17 | -8,000 | 644,489 | -1% | -$3,441,322 | |||||
| D | 2025-10-02 | UTHR | United Therapeutics Corp | Mahon Paul A | EVP, GC | S - Sale+OE | $436.60 | -11,000 | 36,781 | -23% | -$4,802,574 | |||||
2025-09-30 | ANNX | Annexon, Inc. | Carson William H. | Dir | P - Purchase | $3.05 | +4,115 | 42,060 | +11% | +$12,551 | ||||||
2025-09-30 | AMLX | Amylyx Pharmaceuticals, Inc. | Klee Justin B. | Co-CEO | S - Sale | $14.38 | -29,975 | 3,325,301 | -1% | -$430,952 | ||||||
2025-09-30 | AMLX | Amylyx Pharmaceuticals, Inc. | Mazzariello Gina | GC | S - Sale | $14.58 | -8,828 | 148,141 | -6% | -$128,669 | ||||||
2025-09-30 | AMLX | Amylyx Pharmaceuticals, Inc. | Frates James M | CFO | S - Sale | $14.65 | -10,558 | 306,961 | -3% | -$154,650 | ||||||
2025-09-30 | AMLX | Amylyx Pharmaceuticals, Inc. | Cohen Joshua B | Co-CEO | S - Sale | $14.35 | -29,933 | 3,325,347 | -1% | -$429,469 | ||||||
2025-09-30 | AMLX | Amylyx Pharmaceuticals, Inc. | Bedrosian Camille L | Chief Medical Officer | S - Sale | $14.58 | -12,039 | 182,336 | -6% | -$175,518 | ||||||
| M | 2025-09-30 | AIMD | Ainos, Inc. | Taiwan Carbon Nano Technology Corp | 10% | S - Sale | $3.48 | -2,706 | 1,046,206 | 0% | -$9,425 | |||||
| D | 2025-09-30 | AGIO | Agios Pharmaceuticals, Inc. | Scadden David | Dir | S - Sale+OE | $40.00 | -200 | 17,603 | -1% | -$8,000 | |||||
| D | 2025-10-01 | SUPN | Supernus Pharmaceuticals, Inc. | Khattar Jack A. | Pres, CEO | S - Sale+OE | $48.07 | -40,173 | 2,166,470 | -2% | -$1,931,116 | |||||
2025-09-30 | APLS | Apellis Pharmaceuticals, Inc. | Dunlop A. Sinclair | Dir | S - Sale | $22.58 | -31,092 | 188,535 | -14% | -$702,057 | ||||||
2025-10-01 | IMRX | Immuneering Corp | Morales Mallory | Chief Accounting Officer | P - Purchase | $6.39 | +300 | 27,533 | +1% | +$1,917 | ||||||
2025-10-01 | IMRX | Immuneering Corp | Neufeld Leah R | CHIEF PEOPLE OFFICER | P - Purchase | $6.38 | +800 | 23,344 | +4% | +$5,103 | ||||||
2025-10-01 | IMRX | Immuneering Corp | Bookman Michael | GC, SECRETARY | P - Purchase | $6.83 | +1,020 | 4,870 | +26% | +$6,966 | ||||||
| DM | 2025-09-29 | NUVL | Nuvalent, Inc. | Balcom Alexandra | CFO | S - Sale+OE | $85.05 | -27,588 | 61,734 | -31% | -$2,346,256 | |||||
| D | 2025-09-29 | NUVL | Nuvalent, Inc. | Noci Darlene | Chief Development Officer | S - Sale+OE | $83.07 | -4,000 | 48,034 | -8% | -$332,288 | |||||
| D | 2025-10-01 | XENE | Xenon Pharmaceuticals Inc. | Mortimer Ian | Pres, CEO, INTERIM CFO | S - Sale+OE | $40.16 | -25,000 | 45,602 | -35% | -$1,004,000 | |||||
| M | 2025-09-29 | SION | Sionna Therapeutics, Inc. | Booth Bruce | Dir | S - Sale | $30.08 | -78,693 | 3,615,327 | -2% | -$2,367,473 | |||||
| M | 2025-09-29 | CVKD | Cadrenal Therapeutics, Inc. | Szot Matthew K | CFO | S - Sale | $13.99 | -1,800 | 17,133 | -10% | -$25,183 | |||||
| M | 2025-09-29 | CVKD | Cadrenal Therapeutics, Inc. | Pham Quang X | CEO, COB, 10% | S - Sale | $14.01 | -1,300 | 402,633 | 0% | -$18,213 | |||||
| M | 2025-09-29 | MLTX | Moonlake Immunotherapeutics | Chen Bihua | Former 10% Owner | S - Sale | $7.21 | -6,499,978 | 1,994,173 | -77% | -$46,868,184 | |||||
| M | 2025-09-29 | PGEN | Precigen, Inc. | Kindler Jeffrey B | Dir | S - Sale | $3.47 | -174,360 | 346,070 | -34% | -$604,192 | |||||
| D | 2025-09-29 | BCAX | Bicara Therapeutics Inc. | Meisner Lara | GC | S - Sale+OE | $14.75 | -33,807 | 0 | -100% | -$498,653 | |||||
| DM | 2025-09-29 | IONS | Ionis Pharmaceuticals Inc | O'Neil Patrick R. | EVP CLO, GC | S - Sale+OE | $64.62 | -25,300 | 57,130 | -31% | -$1,634,921 | |||||
| D | 2025-09-30 | IONS | Ionis Pharmaceuticals Inc | Geary Richard S | EVP, Chief Development Officer | S - Sale+OE | $65.24 | -57,900 | 79,657 | -42% | -$3,777,668 | |||||
| D | 2025-09-29 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | CFO | S - Sale+OE | $20.40 | -3,250 | 23,000 | -12% | -$66,291 | |||||
| D | 2025-09-29 | KNSA | Kiniksa Pharmaceuticals International, Plc | Tessari Eben | COO | S - Sale+OE | $38.33 | -42,000 | 34,552 | -55% | -$1,609,860 | |||||
| D | 2025-09-29 | UTHR | United Therapeutics Corp | Benkowitz Michael | Pres, COO | S - Sale+OE | $421.80 | -22,500 | 2,648 | -89% | -$9,490,512 | |||||
2025-09-29 | ABEO | Abeona Therapeutics Inc. | O'Malley Brendan M. | SVP, GC | S - Sale | $5.39 | -9,366 | 350,763 | -3% | -$50,516 | ||||||
| M | 2025-09-29 | ABEO | Abeona Therapeutics Inc. | Seshadri Vishwas | CEO | S - Sale | $5.31 | -44,274 | 1,190,067 | -4% | -$234,884 | |||||
2025-09-29 | ABEO | Abeona Therapeutics Inc. | Vazzano Joseph Walter | CFO | S - Sale | $5.39 | -9,035 | 453,631 | -2% | -$48,730 | ||||||
2025-10-01 | CYTK | Cytokinetics Inc | Blum Robert I | Pres, CEO | S - Sale | $55.05 | -5,000 | 372,274 | -1% | -$275,250 | ||||||
2025-10-01 | RMTI | Rockwell Medical, Inc. | Chole Timothy | SVP, CCO | S - Sale | $1.19 | -2,868 | 125,299 | -2% | -$3,413 | ||||||
2025-10-01 | RMTI | Rockwell Medical, Inc. | Neri Jesse | SVP, CFO | S - Sale | $1.19 | -886 | 125,728 | -1% | -$1,054 | ||||||
2025-10-01 | RMTI | Rockwell Medical, Inc. | Strobeck Mark | Pres, CEO | S - Sale | $1.19 | -6,926 | 330,826 | -2% | -$8,242 | ||||||
| D | 2025-09-30 | SUPN | Supernus Pharmaceuticals, Inc. | Khattar Jack A. | Pres, CEO | S - Sale+OE | $48.25 | -8,588 | 2,152,858 | 0% | -$414,371 | |||||
2025-09-30 | PAHC | Phibro Animal Health Corp | Bendheim Jack | Pres, CEO, 10% | S - Sale | $40.38 | -20,664 | 57,514 | -26% | -$834,412 | ||||||
| D | 2025-09-30 | ANAB | Anaptysbio, Inc | Loumeau Eric J | GC | S - Sale+OE | $29.00 | -8,240 | 9,088 | -48% | -$238,960 | |||||
2025-09-30 | LLY | Eli Lilly & Co | Lilly Endowment Inc | 10% | S - Sale | $763.39 | -113,694 | 95,492,993 | 0% | -$86,793,274 | ||||||
2025-09-30 | PEPG | Pepgen Inc. | Oxford Science Enterprises Plc | Former 10% Owner | P - Purchase | $3.20 | +200,000 | 4,955,388 | +4% | +$640,000 | ||||||
2025-09-30 | IMRX | Immuneering Corp | Feinberg Peter | Dir | P - Purchase | $7.03 | +7,500 | 1,133,564 | +1% | +$52,730 | ||||||
| DM | 2025-09-29 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $424.24 | -8,000 | 644,489 | -1% | -$3,393,884 | |||||
| M | 2025-09-26 | ALZN | Alzamend Neuro, Inc. | Ault Milton C III | Dir, 10% | S - Sale | $2.31 | -79,628 | 44,598 | -64% | -$184,156 | |||||
2025-09-29 | RCUS | Arcus Biosciences, Inc. | Azoy Alexander | Chief Accounting Officer | S - Sale | $13.00 | -2,831 | 27,363 | -9% | -$36,803 | ||||||
| D | 2025-09-26 | AGIO | Agios Pharmaceuticals, Inc. | Jones Cecilia | CFO | S - Sale+OE | $36.77 | -3,651 | 33,870 | -10% | -$134,247 | |||||
2025-09-26 | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | S - Sale | $20.25 | -4,000 | 927,688 | 0% | -$81,005 | ||||||
2025-09-26 | ELVN | Enliven Therapeutics, Inc. | Kintz Samuel | Pres, CEO | S - Sale | $20.06 | -3,700 | 915,392 | 0% | -$74,228 | ||||||
2025-09-30 | PGEN | Precigen, Inc. | Kirk Randal J | Dir, 10% | S - Sale | $3.41 | -1,809,667 | 126,912,513 | -1% | -$6,170,964 | ||||||
2025-09-26 | MBX | Mbx Biosciences, Inc. | Heron Patrick J | Dir, 10% | P - Purchase | $18.00 | +666,666 | 5,219,440 | +15% | +$11,999,988 | ||||||
2025-09-26 | CRNX | Crinetics Pharmaceuticals, Inc. | Struthers Richard Scott | Pres, CEO | S - Sale | $45.00 | -4,000 | 1,298,222 | 0% | -$180,000 | ||||||
| D | 2025-09-26 | CRNX | Crinetics Pharmaceuticals, Inc. | Fust Matthew K | Dir | S - Sale+OE | $44.75 | -16,000 | 22,836 | -41% | -$716,000 | |||||
2025-09-26 | PEPG | Pepgen Inc. | Ra Capital Management, L.P. | Dir, 10% | P - Purchase | $3.20 | +9,375,000 | 20,064,545 | +88% | +$30,000,000 | ||||||
2025-09-30 | CYTK | Cytokinetics Inc | Kaye Edward M. Md | Dir | S - Sale | $55.08 | -6,695 | 16,535 | -29% | -$368,761 | ||||||
| D | 2025-09-29 | SUPN | Supernus Pharmaceuticals, Inc. | Khattar Jack A. | Pres, CEO | S - Sale+OE | $48.02 | -10,235 | 2,149,936 | 0% | -$491,485 | |||||
| DM | 2025-09-26 | SION | Sionna Therapeutics, Inc. | Cloonan Michael | Pres, CEO | S - Sale+OE | $29.11 | -25,000 | 547,343 | -4% | -$727,798 | |||||
2025-09-26 | PGEN | Precigen, Inc. | Shah Rutul R | COO | P - Purchase | $3.40 | +2,000 | 405,959 | 0% | +$6,800 | ||||||
2025-09-29 | PGEN | Precigen, Inc. | Tennant Phil | Chief Commercial Officer | P - Purchase | $3.58 | +6,000 | 65,031 | +10% | +$21,480 | ||||||
2025-09-29 | IMRX | Immuneering Corp | Feinberg Peter | Dir | P - Purchase | $7.18 | +5,000 | 1,126,064 | 0% | +$35,900 | ||||||
| M | 2025-09-25 | BYSI | Beyondspring Inc. | Decheng Capital China Life Sciences Usd Fund Iii, L.P. | 10% | S - Sale | $1.69 | -1,800 | 4,354,904 | 0% | -$3,045 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |